

Buy EUR 3.50 Price EUR 1.70 Upside 105.9 %	Value Indicators: EUR DCF: 3.52	Warburg Risk Score: 2.0 Balance Sheet Score: 3.5 Market Liquidity Score: 0.5	Description: Independent power producer (IPP), operating onshore wind and PV projects in Europe
	Market Snapshot: EUR m Market cap: 127.57 No. of shares (m): 75.04 EV: 332.09 Freefloat MC: 92.87 Ø Trad. Vol. (30d): 60.29 th	Shareholders: Freefloat 72.80 % Tion Renewables 21.90 % Union Investment 5.30 %	Key Figures (WRe): 2025e Beta: 0.8 Price / Book: 0.8 x Equity Ratio: 42 % Net Fin. Debt / EBITDA: 7.1 x Net Debt / EBITDA: 7.3 x

Modest start to the year due to weak wind yields


Stated Figures Q1/2025: in EUR m	<table border="1"> <thead> <tr> <th></th> <th>Q1/25</th> <th>Q1/25e</th> <th>Q1/24</th> <th>yoy</th> </tr> </thead> <tbody> <tr> <td>Output (GWh)</td> <td>105.1</td> <td>137.6</td> <td>116.0</td> <td>-9.4%</td> </tr> <tr> <td>Sales</td> <td>9.2</td> <td>10.4</td> <td>10.2</td> <td>-9.7%</td> </tr> <tr> <td>op. EBITDA margin</td> <td>61.0%</td> <td>62.8%</td> <td>70.4%</td> <td>-21.8%</td> </tr> <tr> <td>EBITDA margin</td> <td>61.1%</td> <td>62.8%</td> <td>70.3%</td> <td>-21.5%</td> </tr> </tbody> </table>		Q1/25	Q1/25e	Q1/24	yoy	Output (GWh)	105.1	137.6	116.0	-9.4%	Sales	9.2	10.4	10.2	-9.7%	op. EBITDA margin	61.0%	62.8%	70.4%	-21.8%	EBITDA margin	61.1%	62.8%	70.3%	-21.5%	Comment on Figures: <ul style="list-style-type: none"> Figures were below our expectations due to very weak wind yields in Q1/25. The guidance has been confirmed, which underpins the benefits of a levelled portfolio strategy. EBITDA was also impacted by adverse weather effects and came in at a margin of 61.1%.
	Q1/25	Q1/25e	Q1/24	yoy																							
Output (GWh)	105.1	137.6	116.0	-9.4%																							
Sales	9.2	10.4	10.2	-9.7%																							
op. EBITDA margin	61.0%	62.8%	70.4%	-21.8%																							
EBITDA margin	61.1%	62.8%	70.3%	-21.5%																							

Clearvise released a decent set of figures despite weak wind yields in Q1/25. Germany in particular fell short of our expectations, with production well below the long-term average. However, the technological and local diversification of the portfolio should enable Clearvise to offset the shortfall in Q1 production over the course of the year and reach its guidance. PV already partially offset the onshore wind performance during Q1, with production up 47% compared to Q1/24.

In addition to its existing developer partnerships (clearPartners), Clearvise has extended its footprint in Italy by partnering with OPA United, and intends to add further projects in Italy to its pipeline. Moreover, the French PV project "Chassiecq" achieved grid connection in Q1 and will contribute to this year's P&L. For the Agri-PV project "Triticum" (16.75 MWp), Clearvise has signed a purchase agreement and expects the project to be operational in Q1/26, with 20 years of fixed remuneration. The largest co-development project so far, "La Chatre" (71.5 MWp), secured a long-term tariff for half of its intended capacity, marking an important step towards its successful realisation.

Overall, Clearvise has a well-filled pipeline and is expected to grow its production capacity remarkably in the next years. However, the valuation fails to reflect the strong operative development and the share is trading below its book value. Hence, we stick to our Buy recommendation and reiterate our target price of EUR 3.50 per share.

Changes in Estimates:	<table border="1"> <thead> <tr> <th>FY End: 31.12. in EUR m</th> <th>2025e (old)</th> <th>+ / -</th> <th>2026e (old)</th> <th>+ / -</th> <th>2027e (old)</th> <th>+ / -</th> </tr> </thead> <tbody> <tr> <td>Sales</td> <td>44.13</td> <td>-1.5 %</td> <td>47.87</td> <td>0.0 %</td> <td>49.15</td> <td>0.0 %</td> </tr> <tr> <td>EBITDA</td> <td>28.40</td> <td>-1.8 %</td> <td>32.65</td> <td>0.0 %</td> <td>33.62</td> <td>0.0 %</td> </tr> </tbody> </table>	FY End: 31.12. in EUR m	2025e (old)	+ / -	2026e (old)	+ / -	2027e (old)	+ / -	Sales	44.13	-1.5 %	47.87	0.0 %	49.15	0.0 %	EBITDA	28.40	-1.8 %	32.65	0.0 %	33.62	0.0 %	Comment on Changes: <ul style="list-style-type: none"> We have revised our outlook downwards, positioning ourselves at the midpoint of the confirmed guidance (op. EBITDA of EUR 27.1-29.2m).
FY End: 31.12. in EUR m	2025e (old)	+ / -	2026e (old)	+ / -	2027e (old)	+ / -																	
Sales	44.13	-1.5 %	47.87	0.0 %	49.15	0.0 %																	
EBITDA	28.40	-1.8 %	32.65	0.0 %	33.62	0.0 %																	




Rel. Performance vs CDAX:	
1 month:	-12.4 %
6 months:	-22.3 %
Year to date:	-14.9 %
Trailing 12 months:	-39.8 %

Company events:


FY End: 31.12. in EUR m	CAGR (24-27e)	2021	2022	2023	2024	2025e	2026e	2027e
Sales	10.8 %	32.88	65.16	44.84	36.08	43.46	47.87	49.15
Change Sales yoy		-9.8 %	98.2 %	-31.2 %	-19.5 %	20.4 %	10.1 %	2.7 %
Gross profit margin		98.9 %	99.6 %	98.9 %	100.0 %	100.0 %	100.0 %	100.0 %
EBITDA Margin	14.1 %	21.84	48.17	33.78	22.62	27.88	32.65	33.62
EBIT Margin	29.0 %	66.4 %	73.9 %	75.3 %	62.7 %	64.1 %	68.2 %	68.4 %
EBIT		2.91	30.43	15.38	6.60	8.68	13.20	14.17
Net income	119.8 %	8.8 %	46.7 %	34.3 %	18.3 %	20.0 %	27.6 %	28.8 %
Net income		-3.28	21.32	6.84	0.72	3.03	6.92	7.67
EPS	115.4 %	-0.06	0.34	0.09	0.01	0.04	0.09	0.10
EPS adj.	115.4 %	-0.06	0.34	0.09	0.01	0.04	0.09	0.10
DPS	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCFPS		0.05	0.35	0.21	-0.26	-0.36	0.26	0.36
FCF / Market cap		2.0 %	14.4 %	9.5 %	-13.1 %	-21.3 %	15.4 %	21.2 %
EV / Sales		8.2 x	5.3 x	6.8 x	9.0 x	7.7 x	6.5 x	5.8 x
EV / EBITDA		12.4 x	7.1 x	9.0 x	14.4 x	11.9 x	9.6 x	8.5 x
EV / EBIT		93.1 x	11.3 x	19.8 x	49.2 x	38.3 x	23.7 x	20.2 x
P / E		n.a.	7.1 x	25.0 x	196.0 x	42.5 x	18.9 x	17.0 x
FCF Potential Yield		7.5 %	12.6 %	10.6 %	6.6 %	8.3 %	10.0 %	11.1 %
Net Debt		139.35	190.18	135.43	177.23	204.53	184.81	157.69
ROE		-6.9 %	20.1 %	4.3 %	0.5 %	1.9 %	4.2 %	4.4 %
ROCE (NOPAT)		2.9 %	9.0 %	3.9 %	0.8 %	2.2 %	3.1 %	3.3 %
Guidance:		op. EBITDA of EUR 27.1-29.2m						

Sales development
in EUR m




Source: Warburg Research

Sales by regions
2023; in %



Source: Warburg Research

EBITDA development
in EUR m



Source: Warburg Research


Company Background

- Clearvise is a German IPP, focusing on the operation of European onshore wind and PV parks.
- The acquisition strategy of clearvise is based on three pillars (I) clearValue (II) clearSwitch and (III) clearPartners. The management has expanded the portfolio by more than 140% in only 3 years.
- All three route-to-markets are already proven with at least one successful acquisition. Primary object was the addition of PV projects to diversify the portfolio and optimize output.
- Within the clearScale growth strategy, clearvise targets to reach a portfolio size of 1GW (750MW operating & 250MW pipeline).
- To leverage the company’s development know-how and use the opportunities of new technology’s, the management can allocate up to 20% of the capital into development projects, cooperation or new technologies.

Competitive Quality


- A highly-experienced team of industry experts, capable of operating and optimizing the current portfolio, has developed a lean platform for the integration of further acquisitions.
- Clearvise has introduced a three-pronged market access strategy; clearVALUE, clearPARTNERS and clearSWITCH; to gain a competitive edge and establish a niche market position.
- The market access strategies target the current market as well as the market transition and should allow for profitable growth.
- The technical expertise of the management team and experience with the operation of the former ABO Invest portfolio allows for optimization measures, which will result in higher output.
- By expanding the investment focus of PV projects, the top-line and margins should stabilize further, providing highly visible and predictable cash-flows.

EBIT development
in EUR m




Source: Warburg Research

Output
in GWh



Source: Warburg Research

Net income development
in EUR m



Source: Warburg Research

DCF model

Figures in EUR m	Detailed forecast period			Transitional period																
	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	2038e	2039e	2040e	2041e	2042e	2043e	
Sales	43.5	47.9	49.1	44.2	50.2	49.4	49.6	49.8	49.7	49.9	49.7	50.1	50.9	50.9	51.2	48.1	48.9	51.1	55.2	
Sales change	20.4 %	10.1 %	2.7 %	-10.0 %	13.4 %	-1.6 %	0.5 %	0.5 %	-0.2 %	0.4 %	-0.5 %	0.9 %	1.5 %	0.1 %	0.6 %	-6.2 %	1.8 %	4.4 %	7.9 %	
EBIT	8.7	13.2	14.2	13.9	18.6	18.0	18.2	18.4	18.5	18.7	18.5	18.8	19.5	19.6	19.8	17.3	18.0	19.7	22.9	
EBIT-margin	20.0 %	27.6 %	28.8 %	31.5 %	37.1 %	36.4 %	36.6 %	37.0 %	37.2 %	37.4 %	37.2 %	37.6 %	38.4 %	38.4 %	38.7 %	36.0 %	36.8 %	38.6 %	41.5 %	
Tax rate (EBT)	12.0 %	15.0 %	20.0 %	20.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %		
NOPAT	7.6	11.2	11.3	11.1	14.0	13.5	13.6	13.8	13.9	14.0	13.9	14.1	14.6	14.7	14.9	13.0	13.5	14.8	17.2	
Depreciation in % of Sales	19.2	19.4	19.4	21.1	21.1	21.1	21.1	21.0	20.8	20.8	20.8	20.8	20.7	20.7	20.7	20.7	20.7	20.7	20.7	
Change in provisions	0.0	0.0	0.0	-6.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in liquidity from																				
- Working Capital	0.1	0.1	0.0	2.1	0.4	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.2	0.1	0.1	0.3	
- Capex	49.4	6.5	0.0	28.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Capex in % of Sales	113.7 %	13.7 %	0.0 %	64.3 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC-model)	-22.7	24.0	30.8	-5.0	34.6	34.6	34.7	34.8	34.7	34.8	34.7	34.9	35.3	35.4	35.6	33.9	34.1	35.4	37.6	
PV of FCF	-22.2	22.5	27.4	-4.3	28.1	26.7	25.5	24.4	23.2	22.2	21.1	20.3	19.5	18.7	17.9	16.3	15.6	15.4	15.6	
share of PVs	6.1 %			93.9 %																

																			Term. Value		
2044e	2045e	2046e	2047e	2048e	2049e	2050e	2051e	2052e	2053e	2054e	2055e	2056e	2057e	2058e	2059e	2060e	2061e	2062e	2063e	2064e	
47.5	48.4	39.6	39.9	40.1	40.4	44.8	45.4	46.0	43.6	44.2	44.8	43.7	33.4	33.8	21.3	16.0	16.1	10.6	10.7	10.8	
-13.8 %	1.7 %	-18.2 %	0.8 %	0.5 %	0.8 %	10.7 %	1.3 %	1.3 %	-5.2 %	1.3 %	1.3 %	-2.4 %	-23.5 %	1.3 %	-37.1 %	-24.9 %	1.1 %	-34.4 %	1.0 %	1.0 %	0.0 %
22.9	37.0	30.0	31.3	31.7	32.0	35.4	35.9	36.3	34.5	34.9	35.4	34.5	26.4	26.7	16.8	12.6	12.7	8.4	8.4	8.5	
48.1 %	76.5 %	75.9 %	78.4 %	79.1 %	79.1 %	79.1 %	79.1 %	79.1 %	79.1 %	79.1 %	79.1 %	79.1 %	79.0 %	79.0 %	79.0 %	79.0 %	79.0 %	78.9 %	78.9 %	79.0 %	
25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	
17.2	27.7	22.5	23.5	23.8	24.0	26.5	26.9	27.3	25.8	26.2	26.5	25.9	19.8	20.1	12.6	9.5	9.6	6.3	6.3	6.4	
14.7	1.3	1.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
31.0 %	2.6 %	3.2 %	0.7 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.1 %	0.1 %	0.1 %	0.1 %	0.1 %	0.1 %	
0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
-0.5	0.1	-0.6	0.0	0.0	0.0	0.3	0.0	0.0	-0.2	0.0	0.0	-0.1	-0.7	0.0	-0.8	-0.3	0.0	-0.4	0.0	-0.7	
0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	
0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	2.0	3.0	4.0	
32.4	28.9	24.4	23.7	23.8	24.0	26.3	26.9	27.2	26.0	26.2	26.5	26.0	20.5	20.0	13.4	9.8	8.6	4.6	3.3	3.1	
12.8	10.9	8.8	8.1	7.8	7.5	7.8	7.6	7.4	6.7	6.4	6.2	5.8	4.4	4.1	2.6	1.8	1.5	0.8	0.5	0.5	
																				0.0 %	

Model parameter

Derivation of WACC:		Derivation of Beta:	
Debt ratio	45.0 %	Financial Strength	0.70
Cost of debt	3.0 %	Liquidity	1.00
Market return	8.3 %	Cyclicality	0.60
Risk free rate	2.8 %	Transparency	0.80
Risk premium	5.5 %	Others	0.80
Cost of equity	7.0 %		
WACC	4.88 %	Beta	0.78

Valuation (m)

Present values until 2064e	454.0
Terminal Value	0.0
Financial liabilities	195.1
Pension liabilities	6.7
Hybrid capital	0.0
Minority interest	11.2
Market val. of investments	0.0
Liquidity	24.6
Equity Value	265.6
No. of shares (m)	75.4
Value per share (EUR)	3.52

Sensitivity Value per share (EUR)

Beta	(WACC)	Terminal Growth							Delta EBIT-margin						
		-0.75 %	-0.50 %	-0.25 %	0.00 %	0.25 %	0.50 %	0.75 %	-1.50 pp	-1.00 pp	-0.50 pp	0.0	0.50 pp	1.00 pp	1.50 pp
1.11	(5.9 %)	2.78	2.78	2.78	2.78	2.78	2.78	2.78	2.67	2.70	2.74	2.78	2.82	2.85	2.89
0.95	(5.4 %)	3.13	3.13	3.13	3.13	3.13	3.13	3.13	3.02	3.06	3.09	3.13	3.17	3.21	3.25
0.86	(5.1 %)	3.32	3.32	3.32	3.32	3.32	3.32	3.32	3.20	3.24	3.28	3.32	3.36	3.41	3.45
0.78	(4.9 %)	3.52	3.52	3.52	3.52	3.52	3.52	3.52	3.40	3.44	3.48	3.52	3.57	3.61	3.65
0.70	(4.6 %)	3.73	3.73	3.73	3.73	3.73	3.73	3.73	3.61	3.65	3.69	3.73	3.78	3.82	3.86
0.61	(4.4 %)	3.95	3.95	3.95	3.95	3.95	3.95	3.95	3.82	3.87	3.91	3.95	4.00	4.04	4.09
0.45	(3.9 %)	4.43	4.43	4.43	4.43	4.43	4.43	4.43	4.29	4.34	4.38	4.43	4.48	4.52	4.57

- Our Warburg IPP-DCF approach is a modified valuation approach for the valuation of renewable energy assets.
- Since we can calculate top-line and margin generation of each park over the useful live, we extend our DCF-approach.
- We do not apply a terminal value to our valuation, reflecting the limited life of renewable energy assets.
- For our calculation, we assume a useful life of 30 years for onshore wind and 35 years for PV.
- We only include the current portfolio size of clearwise in our Warburg IPP-DCF.

Valuation	2021	2022	2023	2024	2025e	2026e	2027e
Price / Book	2.3 x	1.0 x	1.1 x	0.9 x	0.8 x	0.8 x	0.7 x
Book value per share ex intangibles	0.88	2.08	2.11	2.12	2.16	2.25	2.35
EV / Sales	8.2 x	5.3 x	6.8 x	9.0 x	7.7 x	6.5 x	5.8 x
EV / EBITDA	12.4 x	7.1 x	9.0 x	14.4 x	11.9 x	9.6 x	8.5 x
EV / EBIT	93.1 x	11.3 x	19.8 x	49.2 x	38.3 x	23.7 x	20.2 x
EV / EBIT adj.*	93.1 x	11.3 x	19.8 x	49.2 x	38.3 x	23.7 x	20.2 x
P / FCF	49.4 x	7.0 x	10.5 x	n.a.	n.a.	6.5 x	4.7 x
P / E	n.a.	7.1 x	25.0 x	196.0 x	42.5 x	18.9 x	17.0 x
P / E adj.*	n.a.	7.1 x	25.0 x	196.0 x	42.5 x	18.9 x	17.0 x
Dividend Yield	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield (on market EV)	7.5 %	12.6 %	10.6 %	6.6 %	8.3 %	10.0 %	11.1 %

*Adjustments made for: -

Company Specific Items	2021	2022	2023	2024	2025e	2026e	2027e
Output in GWh	367	495	534	441	579	614	614

Consolidated profit & loss

In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Sales	32.88	65.16	44.84	36.08	43.46	47.87	49.15
Change Sales yoy	-9.8 %	98.2 %	-31.2 %	-19.5 %	20.4 %	10.1 %	2.7 %
Increase / decrease in inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Own work capitalised	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Sales	32.88	65.16	44.84	36.08	43.46	47.87	49.15
Material expenses	0.35	0.28	0.47	0.00	0.00	0.00	0.00
Gross profit	32.53	64.88	44.37	36.08	43.46	47.87	49.15
<i>Gross profit margin</i>	<i>98.9 %</i>	<i>99.6 %</i>	<i>98.9 %</i>	<i>100.0 %</i>	<i>100.0 %</i>	<i>100.0 %</i>	<i>100.0 %</i>
Personnel expenses	0.66	1.52	1.59	2.28	2.30	2.40	2.46
Other operating income	0.22	0.51	6.67	2.46	1.00	1.00	1.00
Other operating expenses	10.25	15.69	15.67	13.64	14.28	13.82	14.06
Unfrequent items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	21.84	48.17	33.78	22.62	27.88	32.65	33.62
<i>Margin</i>	<i>66.4 %</i>	<i>73.9 %</i>	<i>75.3 %</i>	<i>62.7 %</i>	<i>64.1 %</i>	<i>68.2 %</i>	<i>68.4 %</i>
Depreciation of fixed assets	18.93	17.74	18.41	16.02	19.19	19.45	19.45
EBITA	2.91	30.43	15.38	6.60	8.68	13.20	14.17
Amortisation of intangible assets	0.00	1.25	1.27	0.00	0.00	0.00	0.00
Goodwill amortisation	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT	2.91	30.43	15.38	6.60	8.68	13.20	14.17
<i>Margin</i>	<i>8.8 %</i>	<i>46.7 %</i>	<i>34.3 %</i>	<i>18.3 %</i>	<i>20.0 %</i>	<i>27.6 %</i>	<i>28.8 %</i>
EBIT adj.	2.91	30.43	15.38	6.60	8.68	13.20	14.17
Interest income	0.02	3.39	0.40	0.72	0.40	0.40	0.40
Interest expenses	4.72	7.48	7.40	5.46	5.64	5.46	4.98
Other financial income (loss)	0.02	0.00	0.00	0.00	0.00	0.00	0.00
EBT	-1.81	26.34	8.37	1.86	3.45	8.14	9.59
<i>Margin</i>	<i>-5.5 %</i>	<i>40.4 %</i>	<i>18.7 %</i>	<i>5.1 %</i>	<i>7.9 %</i>	<i>17.0 %</i>	<i>19.5 %</i>
Total taxes	1.47	5.02	1.53	1.13	0.41	1.22	1.92
Net income from continuing operations	-3.28	21.32	6.84	0.72	3.03	6.92	7.67
Income from discontinued operations (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net income before minorities	-3.28	21.32	6.84	0.72	3.03	6.92	7.67
Minority interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net income	-3.28	21.32	6.84	0.72	3.03	6.92	7.67
<i>Margin</i>	<i>-10.0 %</i>	<i>32.7 %</i>	<i>15.2 %</i>	<i>2.0 %</i>	<i>7.0 %</i>	<i>14.5 %</i>	<i>15.6 %</i>
Number of shares, average	53.78	63.45	75.36	75.36	75.36	75.36	75.36
EPS	-0.06	0.34	0.09	0.01	0.04	0.09	0.10
EPS adj.	-0.06	0.34	0.09	0.01	0.04	0.09	0.10

*Adjustments made for:


Guidance: op. EBITDA of EUR 27.1-29.2m

Financial Ratios

	2021	2022	2023	2024	2025e	2026e	2027e
Total Operating Costs / Sales	33.6 %	26.1 %	24.7 %	37.3 %	35.9 %	31.8 %	31.6 %
Operating Leverage	7.0 x	9.7 x	1.6 x	2.9 x	1.5 x	5.1 x	2.8 x
EBITDA / Interest expenses	4.6 x	6.4 x	4.6 x	4.1 x	4.9 x	6.0 x	6.7 x
Tax rate (EBT)	-80.9 %	19.1 %	18.3 %	61.0 %	12.0 %	15.0 %	20.0 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.


Sales, EBITDA

in EUR m




Operating Performance

in %



Performance per Share



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research


Consolidated balance sheet

In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Assets							
Goodwill and other intangible assets	5.57	0.00	0.00	0.11	0.11	0.11	0.11
thereof other intangible assets	0.00	0.00	0.00	0.11	0.11	0.11	0.11
thereof Goodwill	5.57	0.00	0.00	0.00	0.00	0.00	0.00
Property, plant and equipment	191.33	352.58	291.46	327.75	357.95	345.05	325.60
Financial assets	0.19	0.88	0.90	0.52	0.52	0.52	0.52
Other long-term assets	0.00	0.05	2.64	0.07	0.07	0.07	0.07
Fixed assets	197.09	353.51	295.01	328.45	358.65	345.75	326.30
Inventories	0.29	0.23	0.00	0.10	0.10	0.20	0.20
Accounts receivable	5.85	6.20	5.18	4.14	5.00	5.50	5.60
Liquid assets	23.20	77.67	47.99	24.58	4.15	5.81	18.43
Other short-term assets	4.49	13.74	14.91	19.00	19.00	19.00	19.00
Current assets	33.83	97.84	68.08	47.82	28.25	30.51	43.23
Total Assets	230.90	451.30	363.10	376.30	386.90	376.30	369.50
Liabilities and shareholders' equity							
Subscribed capital	57.40	75.36	75.36	75.36	75.36	75.36	75.36
Capital reserve	25.59	44.75	44.75	44.75	44.75	44.75	44.75
Retained earnings	0.99	0.00	0.00	-0.61	2.42	9.34	17.02
Other equity components	-27.78	35.84	39.00	40.22	40.22	40.22	40.22
Shareholders' equity	56.20	155.95	159.11	159.72	162.75	169.67	177.34
Minority interest	4.88	0.00	0.01	0.10	0.10	0.10	0.10
Total equity	61.08	155.95	159.11	159.82	162.85	169.77	177.44
Provisions	3.02	12.54	11.92	8.34	8.34	8.34	8.34
thereof provisions for pensions and similar obligations	0.00	7.08	6.31	6.69	6.69	6.69	6.69
Financial liabilities (total)	162.55	260.76	177.11	195.12	201.99	183.93	169.43
Short-term financial liabilities	0.00	51.52	28.20	18.23	8.23	0.00	0.00
Accounts payable	1.42	5.81	2.61	3.67	4.40	4.90	5.00
Other liabilities	2.88	16.29	12.33	9.32	9.32	9.32	9.32
Liabilities	169.86	295.40	203.97	216.45	224.04	206.49	192.08
Total liabilities and shareholders' equity	230.90	451.30	363.10	376.30	386.90	376.30	369.50


Financial Ratios

	2021	2022	2023	2024	2025e	2026e	2027e
Efficiency of Capital Employment							
Operating Assets Turnover	0.2 x	0.2 x	0.2 x	0.1 x	0.1 x	0.1 x	0.2 x
Capital Employed Turnover	0.2 x	0.2 x	0.2 x	0.1 x	0.1 x	0.1 x	0.1 x
ROA	-1.7 %	6.0 %	2.3 %	0.2 %	0.8 %	2.0 %	2.4 %
Return on Capital							
ROCE (NOPAT)	2.9 %	9.0 %	3.9 %	0.8 %	2.2 %	3.1 %	3.3 %
ROE	-6.9 %	20.1 %	4.3 %	0.5 %	1.9 %	4.2 %	4.4 %
Adj. ROE	-6.9 %	20.1 %	4.3 %	0.5 %	1.9 %	4.2 %	4.4 %
Balance sheet quality							
Net Debt	139.35	190.18	135.43	177.23	204.53	184.81	157.69
Net Financial Debt	139.35	183.10	129.12	170.54	197.84	178.12	151.00
Net Gearing	228.2 %	121.9 %	85.1 %	110.9 %	125.6 %	108.9 %	88.9 %
Net Fin. Debt / EBITDA	638.2 %	380.1 %	382.2 %	754.0 %	709.7 %	545.5 %	449.1 %
Book Value / Share	1.0	2.1	2.1	2.1	2.2	2.3	2.4
Book value per share ex intangibles	0.9	2.1	2.1	2.1	2.2	2.3	2.4


ROCE Development



Net debt in EUR m



Book Value per Share in EUR



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research


Consolidated cash flow statement

In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Net income	-3.28	21.32	6.84	0.72	3.03	6.92	7.67
Depreciation of fixed assets	18.93	16.49	17.13	16.02	19.19	19.45	19.45
Amortisation of goodwill	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Amortisation of intangible assets	0.00	1.25	1.27	0.00	0.00	0.00	0.00
Increase/decrease in long-term provisions	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other non-cash income and expenses	5.25	10.62	-8.68	-1.94	0.00	0.00	0.00
Cash Flow before NWC change	20.90	49.68	16.56	14.81	22.23	26.37	27.12
Increase / decrease in inventory	-1.19	0.00	0.00	0.00	0.00	-0.10	0.00
Increase / decrease in accounts receivable	-1.23	0.00	0.00	0.00	-0.86	-0.50	-0.10
Increase / decrease in accounts payable	0.00	0.00	0.00	0.00	0.73	0.50	0.10
Increase / decrease in other working capital positions	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / decrease in working capital (total)	-2.42	0.00	0.00	0.00	-0.13	-0.10	0.00
Net cash provided by operating activities [1]	18.48	49.68	16.56	14.81	22.10	26.27	27.12
Investments in intangible assets	0.00	0.00	0.00	-0.11	0.00	0.00	0.00
Investments in property, plant and equipment	-15.82	-27.79	-0.45	-34.05	-49.39	-6.55	0.00
Payments for acquisitions	-14.54	-27.21	-9.81	0.69	0.00	0.00	0.00
Financial investments	0.00	0.00	0.06	0.00	0.00	0.00	0.00
Income from asset disposals	0.00	0.00	0.01	2.90	0.00	0.00	0.00
Net cash provided by investing activities [2]	-30.35	-55.00	9.21	-28.61	-49.39	-6.55	0.00
Change in financial liabilities	1.69	26.50	-48.59	-5.40	6.87	-18.05	-14.50
Dividends paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of own shares	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital measures	20.72	37.12	0.00	0.00	0.00	0.00	0.00
Other	-4.68	-3.89	-6.87	-4.21	0.00	0.00	0.00
Net cash provided by financing activities [3]	17.73	59.73	-55.45	-9.61	6.87	-18.05	-14.50
Change in liquid funds [1]+[2]+[3]	5.86	54.42	-29.68	-23.41	-20.43	1.67	12.62
Effects of exchange-rate changes on cash	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash and cash equivalent at end of period	23.18	77.62	47.99	24.58	4.15	5.81	18.43

Financial Ratios


	2021	2022	2023	2024	2025e	2026e	2027e
Cash Flow							
FCF	2.66	21.89	16.12	-19.35	-27.29	19.72	27.12
Free Cash Flow / Sales	8.1 %	33.6 %	35.9 %	-53.6 %	-62.8 %	41.2 %	55.2 %
Free Cash Flow Potential	20.37	43.15	32.25	21.49	27.46	31.43	31.70
Free Cash Flow / Net Profit	-81.0 %	102.7 %	235.7 %	-2677.5 %	-900.2 %	285.0 %	353.5 %
Interest Received / Avg. Cash	0.1 %	6.7 %	0.6 %	2.0 %	2.8 %	8.0 %	3.3 %
Interest Paid / Avg. Debt	3.1 %	3.5 %	3.4 %	2.9 %	2.8 %	2.8 %	2.8 %
Management of Funds							
Investment ratio	48.1 %	42.7 %	1.0 %	94.7 %	113.7 %	13.7 %	0.0 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	83.6 %	156.6 %	2.4 %	213.2 %	257.3 %	33.7 %	0.0 %
Avg. Working Capital / Sales	14.2 %	4.1 %	3.6 %	4.4 %	1.5 %	1.6 %	1.6 %
Trade Debtors / Trade Creditors	413.1 %	106.7 %	198.6 %	112.8 %	113.6 %	112.2 %	112.0 %
Inventory Turnover	1.2 x	1.2 x	n.a.	0.0 x	0.0 x	0.0 x	0.0 x
Receivables collection period (days)	65	35	42	42	42	42	42
Payables payment period (days)	1,460	7,496	2,020	n.a.	n.a.	n.a.	n.a.
Cash conversion cycle (Days)	-1,094	-7,162	n.a.	n.a.	n.a.	n.a.	n.a.

CAPEX and Cash Flow in EUR m




Source: Warburg Research

Free Cash Flow Generation



Source: Warburg Research

Working Capital



Source: Warburg Research

LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- 1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- 2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- 3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- 4- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- 5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- 6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- 6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- 6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- 7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Clearvise	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A1EWXA4.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	141	71
Hold	47	24
Sell	6	3
Rating suspended	5	3
Total	199	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	36	72
Hold	10	20
Sell	1	2
Rating suspended	3	6
Total	50	100

PRICE AND RATING HISTORY CLEARVISE AS OF 14.05.2025



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode +49 40 3282-2678
Head of Equities mrode@mmwarburg.com

RESEARCH

Michael Heider +49 40 309537-280
Head of Research mheider@warburg-research.com

Henner Rüschemeyer +49 40 309537-270
Head of Research hrueschmeier@warburg-research.com

Stefan Augustin +49 40 309537-168
Cap. Goods, Engineering saugustin@warburg-research.com

Jan Bauer +49 40 309537-155
Renewables jbauer@warburg-research.com

Christian Cohrs +49 40 309537-175
Industrials & Transportation ccohrs@warburg-research.com

Dr. Christian Ehmann +49 40 309537-167
BioTech, Life Science cehmann@warburg-research.com

Felix Ellmann +49 40 309537-120
Software, IT fellmann@warburg-research.com

Jörg Philipp Frey +49 40 309537-258
Retail, Consumer Goods jfrey@warburg-research.com

Marius Fuhrberg +49 40 309537-185
Financial Services mfuhrberg@warburg-research.com

Fabio Hölscher +49 40 309537-240
Automobiles, Car Suppliers fhoelscher@warburg-research.com

Philipp Kaiser +49 40 309537-260
Real Estate, Construction pkaiser@warburg-research.com

Thilo Kleibauer +49 40 309537-257
Retail, Consumer Goods tkleibauer@warburg-research.com

Hannes Müller +49 40 309537-255
Software, IT hmueller@warburg-research.com

Andreas Pläsier +49 40 309537-246
Banks, Financial Services aplaesier@warburg-research.com

Malte Schaumann +49 40 309537-170
Technology mschaumann@warburg-research.com

Oliver Schwarz +49 40 309537-250
Chemicals, Agriculture oschwarz@warburg-research.com

Simon Stippig +49 40 309537-265
Real Estate, Telco sstippig@warburg-research.com

Marc-René Tonn +49 40 309537-259
Automobiles, Car Suppliers mtonn@warburg-research.com

Robert-Jan van der Horst +49 40 309537-290
Technology rvanderhorst@warburg-research.com

Andreas Wolf +49 40 309537-140
Software, IT awolf@warburg-research.com

INSTITUTIONAL EQUITY SALES

Klaus Schilling +49 69 5050-7400
Head of Equity Sales, Germany kschilling@mmwarburg.com

Tim Beckmann +49 40 3282-2665
United Kingdom tbeckmann@mmwarburg.com

Jens Buchmüller +49 69 5050-7415
Scandinavia, Austria jbuchmueller@mmwarburg.com

Matthias Fritsch +49 40 3282-2696
United Kingdom, Ireland mfritsch@mmwarburg.com

Rudolf Alexander Michaelis +49 40 3282-2649
Germany rmichaelis@mmwarburg.com

Roman Alexander Niklas +49 69 5050-7412
Switzerland, Poland, Italy rniklas@mmwarburg.com

Sascha Propp +49 40 3282-2656
France spropp@mmwarburg.com

Leyan Ilkbahar +49 40 3282-2695
Roadshow/Marketing liikbahar@mmwarburg.com

Antonia Möller +49 69 5050-7417
Roadshow/Marketing amoeller@mmwarburg.com

Juliane Niemann +49 40 3282-2694
Roadshow/Marketing jniemann@mmwarburg.com

SALES TRADING

Oliver Merckel +49 40 3282-2634
Head of Sales Trading omerckel@mmwarburg.com

Bastian Quast +49 40 3282-2701
Sales Trading bquast@mmwarburg.com

Christian Salomon +49 40 3282-2685
Sales Trading csalomon@mmwarburg.com

DESIGNATED SPONSORING

Sebastian Schulz +49 40 3282-2631
Designated Sponsoring sschulz@mmwarburg.com

Jörg Treptow +49 40 3282-2658
Designated Sponsoring jtreptow@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572
Macro Research cklude@mmwarburg.com

Dr. Christian Jasperneite +49 40 3282-2439
Investment Strategy cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research research.mmwarburg.com/en/index.html
Bloomberg RESP MMWA GO
FactSet www.factset.com

LSEG www.lseg.com
Capital IQ www.capitaliq.com

For access please contact:

Andrea Schaper +49 40 3282-2632
Sales Assistance aschaper@mmwarburg.com

Kerstin Muthig +49 40 3282-2703
Sales Assistance kmuthig@mmwarburg.com